Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
44 hedge funds and large institutions have $222M invested in Impel Pharmaceuticals Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
49% more capital invested
Capital invested by funds: $150M → $222M (+$72.8M)
33% more funds holding
Funds holding: 33 → 44 (+11)
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
5.21% more ownership
Funds ownership: 75.93% → 81.15% (+5.2%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
+$4.84M |
| 2 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$4.51M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$2.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.62M |
| 5 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$2.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
-$2.02M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$469K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$284K |
| 4 |
D.E. Shaw & Co
New York
|
-$240K |
| 5 |
ZP
Zimmer Partners
New York
|
-$221K |
IMPL Hedge Fund Activity: Q3 2021 in Review
44 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q3 2021, worth a combined $222M — up 49% from $150M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IMPL positions and 5 closed out — a net gain of 11 holders — while 12 added to existing stakes and 9 trimmed.
The largest buyer was Kohlberg Kravis Roberts & Co, adding an estimated $4.84M. The largest seller was Davidson Kempner Capital Management, exiting entirely with an estimated $2.02M sold.
- 44 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q3 2021, up from 33 in Q2 2021.
- Funds reported $222M of Impel Pharmaceuticals Inc. Common Stock stock for Q3 2021, up 49% quarter-over-quarter.
- 16 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q3 2021 and 5 closed out, a net change of +11 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q3 2021 was Kohlberg Kravis Roberts & Co, an estimated $4.84M added.
- The largest Impel Pharmaceuticals Inc. Common Stock seller in Q3 2021 was Davidson Kempner Capital Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q3 2021.